** Shares of drug maker Kala Bio KALA.O fall 34.6% to $7.12, set for record single-day fall
** Company says its CEO Mark Iwicki has resigned, and President Todd Bazemore has been appointed as interim CEO
** Iwicki has been with KALA for nearly a decade
** Iwicki will continue as chair of the board
** KALA is set to report mid-stage trial data of its drug, KPI-012, in the second quarter of 2025, for the treatment of persistent corneal epithelial defects, a condition where injuries to the cornea, the clear front part of the eye, don't heal properly
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。